Common use of Expenses of the Representative Clause in Contracts

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative a management fee equal to 1.0% of the gross proceeds received by the Company from the sale of the Public Securities and (ii) reimburse the Representative for its reasonable and documented out-of-pocket expenses related to the Offering in an amount up to $135,000 in the aggregate, which shall be paid by deduction from the proceeds of the Offering contemplated herein.

Appears in 3 contracts

Sources: Underwriting Agreement (Peraso Inc.), Underwriting Agreement (Peraso Inc.), Underwriting Agreement (Peraso Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative a management fee equal to 1.0% of the gross proceeds received by the Company from the sale of the Public Securities and (ii) will reimburse the Representative for its reasonable and documented out-of-pocket expenses related to the Offering in an amount up to an aggregate of $135,000 in 85,000 (which shall include any expenses incurred under clauses (m) and (n) of Section 4.5(a) herein), $15,000 of which has been paid prior to the aggregatedate hereof, which shall be paid by deduction from the proceeds of the Offering contemplated herein.

Appears in 3 contracts

Sources: Underwriting Agreement (Cyclacel Pharmaceuticals, Inc.), Underwriting Agreement (Cyclacel Pharmaceuticals, Inc.), Underwriting Agreement (Cyclacel Pharmaceuticals, Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), that on the Closing Date and each Option Closing DateDate (if any), if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.0% of the total gross proceeds received by raised in the Company from Offering on the sale of the Public Securities Closing Date and each Option Closing Date, if any, (ii) reimburse the Representative up to $145,000 for its reasonable fees and documented expenses of legal counsel and other out-of-pocket expenses related to the Offering in an amount up to $135,000 in the aggregateexpenses, which shall be paid by deduction from the proceeds of the Offering contemplated hereinherein (the “Fee Cap”).

Appears in 3 contracts

Sources: Underwriting Agreement (Intelligent Bio Solutions Inc.), Underwriting Agreement (Intelligent Bio Solutions Inc.), Underwriting Agreement (Intelligent Bio Solutions Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), that on the Closing Date and or Option Closing Date, if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.0% of the total gross proceeds received by raised in the Company from Offering on the sale of the Public Securities Closing Date and each Option Closing Date, if any, (ii) reimburse the Representative up to $145,000 for its reasonable fees and documented expenses of legal counsel and other out-of-pocket expenses related to the Offering in an amount up to $135,000 in the aggregateexpenses, which shall be paid by deduction from the proceeds of the Offering contemplated hereinherein (the “Fee Cap”).

Appears in 2 contracts

Sources: Underwriting Agreement (Intelligent Bio Solutions Inc.), Underwriting Agreement (Intelligent Bio Solutions Inc.)

Expenses of the Representative. The Company further agrees that, that in addition to the aggregate and including the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and each Option Closing Date, if applicableany, it will (i) pay to the Representative a management fee equal to 1.0% of the gross proceeds received by the Company from the sale of the Public Securities and (ii) will reimburse the Representative for its reasonable and documented out-of-pocket expenses related to the Offering in an amount up to $135,000 Offering, which shall not, in the aggregate, which shall be paid exceed $20,000 in pre-Closing Date expenses and up to an aggregate of $95,000 in total expenses by deduction from the proceeds of the Offering contemplated herein.

Appears in 2 contracts

Sources: Underwriting Agreement (Viveve Medical, Inc.), Underwriting Agreement (Viveve Medical, Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative (i) a management fee equal to 1.0% of the gross proceeds received by raised in the Company from the sale of the Public Securities and Offering, (ii) reimburse a $50,000 non-accountable expense allowance, (iii) up to $90,000 for the Representative for its reasonable legal and documented other out-of-pocket expenses related to of the Offering in an amount up to Representative, and (iv) $135,000 in the aggregate, which shall be paid 12,900 for clearing expenses by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Cocrystal Pharma, Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it the Company will (i) pay to reimburse the Representative a management fee equal to 1.0% for its reasonable legal and other out-of-pocket expenses of the gross proceeds received by the Company from the sale Offering in an amount of the Public Securities up to an aggregate of $75,000 (which shall include any expenses under (k) and (l) in Section 4.5(a) herein) and (ii) reimburse the Representative for its reasonable and documented out-of-pocket clearing expenses related to the Offering in an amount of up to $135,000 in the aggregate12,900, which shall be paid by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Marathon Patent Group, Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative a management fee equal to 1.00.35% of the gross proceeds received by the Company from the sale of the Public Securities and (ii) reimburse Securities, up to $90,000 for the Representative for its reasonable and documented Representative’s out-of-pocket expenses related to expense, and $12,900 for the Offering in an amount up to $135,000 in clearing firm of the aggregateRepresentative, which shall be paid by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Iterum Therapeutics PLC)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative (i) a management fee equal to 1.0% of the gross proceeds received by raised in the Company from the sale of the Public Securities and Offering, (ii) reimburse a $50,000 non-accountable expense allowance, (iii) up to $90,000 for the Representative for its reasonable legal and documented other out-of-pocket expenses related to of the Offering in an amount up to Representative, and (iv) $135,000 in the aggregate, which shall be paid 15,950 for clearing expenses by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Cocrystal Pharma, Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.01% of the aggregate gross proceeds received by the Company from the sale of the Public Securities Offering (the “Management Fee”) and (ii) reimburse the Representative for its reasonable expenses of the Offering in the non-accountable sum of $35,000 and for its legal and other documented out-of-pocket expenses related to of the Offering in an amount of up to an aggregate of $135,000 in the aggregate, which shall be paid 100,000 by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Diffusion Pharmaceuticals Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.01% of the aggregate gross proceeds received by the Company from the sale of the Public Securities Offering, (ii) pay the Representative $25,000 for its non-accountable expenses, and (iiiii) reimburse the Representative for its reasonable legal and other documented out-of-pocket expenses related to of the Offering in an amount of up to an aggregate of $135,000 in the aggregate, which shall be paid 100,000 by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Diffusion Pharmaceuticals Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.01% of the aggregate gross proceeds received by the Company from the sale of the Public Securities Offering, (ii) pay the Representative $50,000 for its non-accountable expenses, and (iiiii) reimburse the Representative for its reasonable legal and other documented out-of-pocket expenses related to of the Offering in an amount of up to an aggregate of $135,000 in the aggregate, which shall be paid 100,000 by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Diffusion Pharmaceuticals Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative (i) a management fee equal to 1.0% of the gross proceeds received by the Company from the sale of the Public Securities Offering, and (ii) reimburse the Representative for its reasonable and documented all reasonable, out-of-pocket expenses related incurred, including travel, databases, fees and disbursements of legal counsel, and of other consultants and advisors not to exceed $250,000 without the Offering in an amount up to $135,000 in the aggregate, which shall be paid Company's prior consent by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Algernon Pharmaceuticals Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.01% of the aggregate gross proceeds received by the Company from the sale of the Public Securities Offering and (ii) reimburse the Representative for its reasonable legal and other documented out-of-pocket expenses related to of the Offering in an amount of up to an aggregate of $135,000 in the aggregate, which shall be paid 100,000 by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Diffusion Pharmaceuticals Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative (i) a management fee equal to 1.0% of the gross proceeds received by the Company from the sale of the Public Securities Offering, and (ii) reimburse the Representative for its reasonable and documented all reasonable, out-of-pocket expenses related incurred, including travel, databases, fees and disbursements of legal counsel, and of other consultants and advisors not to exceed $100,000 without the Offering in an amount up to $135,000 in the aggregate, which shall be paid Company's prior consent by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Algernon Pharmaceuticals Inc.)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a4.5(a), on the Closing Date and Option Closing Date, if applicable, it will (i) pay to the Representative a management fee equal to 1.0% of the gross proceeds received by the Company from the sale of the Public Securities and (ii) will reimburse the Representative for its reasonable and documented out-of-pocket expenses related to the Offering in an amount up to an aggregate of $135,000 in 130,000 (which shall include any expenses incurred under clauses (m) and (n) of Section 4.5(a) herein), $25,000 of which has been paid prior to the aggregatedate hereof, which shall be paid by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (EnteroMedics Inc)

Expenses of the Representative. The Company further agrees that, in addition to the expenses payable pursuant to Section 4.6(a), on the Closing Date and Option Closing Date, if applicable, it the Company will (i) pay to the Representative a management fee equal to 1.0% non-accountable expenses allowance of the gross proceeds received by the Company from the sale of the Public Securities and $25,000, (ii) reimburse the Representative for its reasonable legal and other documented out-of-pocket expenses related to of the Offering in an amount of up to an aggregate of $135,000 100,000, and (iii) reimburse the Representative for its clearing expenses in the aggregate, which shall be paid amount of $10,000 by deduction from the proceeds of the Offering contemplated herein.

Appears in 1 contract

Sources: Underwriting Agreement (Bellerophon Therapeutics, Inc.)